PE Week Wire — 7/20/06

Gilead Sciences Inc. (Nasdaq: GILD) has exercised its option to purchase Corus Pharma Inc., a Seattle-based drug company focused on respiratory diseases. The deal is valued at $365 million, and is expected to close later this quarter. Gilead became Corus' second-largest shareholder this past April via a $25 million investment, and also received an exclusive option to purchase the remaining Corus shares. Corus previously had raised around $123 million in total VC funding, including a $65 million Series C round in early 2004 at a post-money valuation of approximately $155 million. Other shareholders include Burrill & Co., JPMorgan Partners, MDS Health Ventures, OrbiMed Advisors, RBC Capital Partners, Integra Ventures, Bear Stearns Health Innoventures, Anthem Venture Partners, Novo AS, Pacific Rim Ventures and SunAmerica Ventures.

Amalgamated Bean Coffee Trading Co. Ltd., an India-based integrated coffee conglomerate, has raised $20 million from Sequoia Capital India.

GUS PLC yesterday reiterated plans to de-merge its credit information unit (Experian) and retail unit (Argos and Homebase), despite a